Important Dates for the CRISPR Medicine Conference 2024
Before the Event:
- September 1st, 2023: Registration & abstract submissions open
- January 12th, 2024: Early bird registration deadline
- January 24th, 2024: Abstract submission deadline
- February 16th, 2024: Oral and poster notifications & final programme available
- April 21st, 2024: Registration deadline
- April 22nd, 2024: Abstract publication in the CRISPR Medicine News portal
- April 22nd, 2024: Virtual event
- April 23-25th, 2024: In-person event in Copenhagen, Denmark
The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25th April 2024 (virtual event 22nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.
This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.
You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 20,000 readers per month.
Once you have registered, you will be able to explore the content and see the list of participants.
**CRISPRMED24 Newsletter - Sign up here**
San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).
For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.
Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.
San Raffaele - Telethon Institute for Gene Therapy, Italy
National Institute of Standards & Technology, USA
Leader of the Gene Editing Program at the National Institute of Standards & Technology.
UCL Great Ormond Street Institute of Child Health, UK
· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN
· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News
Attendees (confirmed) - Companies and Organisations
Attendees (confimed) - Investors
List of reviewers
August 1, 2023 - 00:00 until April 21, 2024 - 18:00
August 1, 2023 - 12:00 until January 24, 2024 - 18:00
If you have any questions, please contact email@example.com .